Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00

Repare Therapeutics (NASDAQ:RPTX) had its price target trimmed by Stifel Nicolaus from $9.00 to $4.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Friday, November 8th.

Repare Therapeutics Stock Down 55.4 %

NASDAQ RPTX opened at $1.77 on Friday. The stock’s 50-day simple moving average is $3.30 and its two-hundred day simple moving average is $3.35. Repare Therapeutics has a twelve month low of $1.66 and a twelve month high of $8.49. The company has a market capitalization of $75.24 million, a price-to-earnings ratio of -0.89 and a beta of 0.71.

Institutional Investors Weigh In On Repare Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP raised its holdings in Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after buying an additional 250,000 shares during the last quarter. Renaissance Technologies LLC increased its position in Repare Therapeutics by 30.7% during the 2nd quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock valued at $1,514,000 after purchasing an additional 107,700 shares during the period. Acadian Asset Management LLC raised its holdings in Repare Therapeutics by 212.1% in the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after purchasing an additional 284,036 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Repare Therapeutics by 428.4% during the 2nd quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock valued at $472,000 after purchasing an additional 115,916 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Repare Therapeutics by 5.4% during the second quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares during the period. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.